All In Biotech

Drug Trial Radar · NCT05317858

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Aug 12, 2022

Primary completion

Jun 1, 2031

Study completion Dec 1, 2031

Sponsor

Lead sponsor
InSightecIndustry
Sponsor type
Industry
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.

Conditions

  • Brain Tumor
  • Non Small Cell Lung Cancer

Interventions

  • Blood Brain Barrier Opening - OncologyDevice

    BBB opening via Exablate Type 2 system with microbubble resonators on the day of ICI infusion to treat brain metastases.

  • PembrolizumabDrug

    Pembrolizumab infusion

  • AtezolizumabDrug

    Atezolizumab infusion

  • CemiplimabDrug

    Cemiplimab infusion

  • NivolumabDrug

    Nivolumab infusion

  • IptilimumabDrug

    Iptilimumab infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: up to 6 months
  2. tumor lesion(s) on the MRI imagesTime frame: up to 6 months

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Withdrawn

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Broward Health

    Fort Lauderdale, Florida · Recruiting

  • Miami Cancer Institute at Baptist Health

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • UPMC Presbyterian Hospital - University of Pittsburgh

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Johnston Willis Hospital

    Richmond, Virginia · Active not recruiting

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Active not recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital, Yonsei University Health System

    Soeul, South Korea · Not yet recruiting

  • Samsung Medical Center

    Seoul, Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.